TPI 287
TPI 287 is a pharmaceutical drug with 12 clinical trials. Historical success rate of 20.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
18.2%
2 of 11 finished
81.8%
9 ended early
0
trials recruiting
12
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
Clinical Trials (12)
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
TPI 287 in Breast Cancer Metastatic to the Brain
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
TPI 287 in Patients With Recurrent Glioblastoma Multiforme
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
All 12 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 12